The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy

Adv Cancer Res. 2002;86:113-48. doi: 10.1016/s0065-230x(02)86004-3.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes / immunology
  • Cancer Vaccines / classification
  • Cancer Vaccines / therapeutic use
  • DNA, Viral / genetics
  • Female
  • Genes, Viral
  • Genetic Vectors / therapeutic use
  • HLA Antigens / immunology
  • Humans
  • Immunity, Cellular
  • Immunologic Surveillance
  • Immunotherapy*
  • Mice
  • Mice, Transgenic
  • Oncogene Proteins, Viral / genetics
  • Oncogene Proteins, Viral / physiology
  • Papillomaviridae / genetics
  • Papillomaviridae / immunology
  • Papillomaviridae / pathogenicity*
  • Papillomavirus Infections / epidemiology
  • Papillomavirus Infections / immunology*
  • Papillomavirus Infections / virology
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocytes, Cytotoxic / immunology
  • Tumor Escape
  • Tumor Virus Infections / epidemiology
  • Tumor Virus Infections / immunology*
  • Tumor Virus Infections / virology
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / immunology*
  • Uterine Cervical Neoplasms / therapy
  • Uterine Cervical Neoplasms / virology

Substances

  • Cancer Vaccines
  • DNA, Viral
  • HLA Antigens
  • Oncogene Proteins, Viral